Individuals with narcolepsy or idiopathic hypersomnia have a substantially higher prevalence of sodium-relevant comorbidity risk factors compared to matched individuals without these conditions, suggesting careful management including limiting sodium exposure may mitigate clinical burden.
Key Findings
Results
Individuals with narcolepsy had a substantially higher prevalence of at least one sodium-relevant risk factor compared to those without narcolepsy.
69.2% of individuals with narcolepsy had at least one sodium-relevant risk factor vs 43.6% in the non-narcolepsy cohort
The narcolepsy cohort included 29,317 individuals and the non-narcolepsy cohort included 146,585 individuals
Cohorts were entropy balanced on age, sex, race/ethnicity, region of residence, health plan type, and year of index
Data were drawn from Komodo Research Data covering 01/01/2016 to 01/31/2024
Risk factors were assessed in the 12-month pre-index period defined by diagnosis, treatment, or procedure code(s)
Results
Individuals with idiopathic hypersomnia had a substantially higher prevalence of at least one sodium-relevant risk factor compared to those without idiopathic hypersomnia.
74.4% of individuals with IH had at least one sodium-relevant risk factor vs 43.0% in the non-IH cohort
The IH cohort included 11,951 individuals and the non-IH cohort included 59,755 individuals
The prevalence in those with IH (74.4%) was slightly higher than in those with narcolepsy (69.2%)
Non-IH cohort index date was a random date to serve as a comparator
Results
Cardiovascular comorbidities were more prevalent in individuals with narcolepsy compared to those without narcolepsy.
40.8% of individuals with narcolepsy had cardiovascular conditions vs 27.8% in the non-narcolepsy cohort
Cardiovascular conditions were among the sodium-relevant risk factors identified through literature review
The difference represents approximately a 13 percentage point higher prevalence in the narcolepsy group
Results
Cardiometabolic comorbidities were more prevalent in individuals with narcolepsy compared to those without narcolepsy.
49.9% of individuals with narcolepsy had cardiometabolic conditions vs 35.8% in the non-narcolepsy cohort
The difference represents approximately a 14 percentage point higher prevalence in the narcolepsy group
Cardiometabolic conditions were classified as a distinct category of sodium-relevant risk factors
Results
Renal comorbidities were more prevalent in individuals with narcolepsy compared to those without narcolepsy.
5.3% of individuals with narcolepsy had renal conditions vs 3.0% in the non-narcolepsy cohort
Renal conditions were included as sodium-relevant risk factors alongside cardiovascular, cardiometabolic, liver cirrhosis, and sleep apnea
Results
Cardiovascular comorbidities were more prevalent in individuals with idiopathic hypersomnia compared to those without the condition.
40.2% of individuals with IH had cardiovascular conditions vs 26.5% in the non-IH cohort
The difference represents approximately a 13.7 percentage point higher prevalence in the IH group
Results
Cardiometabolic comorbidities were more prevalent in individuals with idiopathic hypersomnia compared to those without the condition.
51.8% of individuals with IH had cardiometabolic conditions vs 35.3% in the non-IH cohort
The difference represents approximately a 16.5 percentage point higher prevalence in the IH group
Cardiometabolic prevalence in those with IH (51.8%) was slightly higher than in those with narcolepsy (49.9%)
Results
Renal comorbidities were more prevalent in individuals with idiopathic hypersomnia compared to those without the condition.
4.2% of individuals with IH had renal conditions vs 2.6% in the non-IH cohort
Renal comorbidity prevalence in IH (4.2%) was slightly lower than in narcolepsy (5.3%)
Methods
Sodium-relevant risk factors were identified through a literature review and encompassed cardiovascular, cardiometabolic, and renal comorbidities, liver cirrhosis, and sleep apnea.
The selection of risk factors was grounded in the clinical rationale that excess sodium intake may confer negative clinical outcomes
Risk factor presence was defined by diagnosis, treatment, or procedure codes in the 12-month pre-index period
The study used Komodo Research Data, a real-world claims-based database
Index date for narcolepsy/IH patients was the first diagnosis; index date for comparators was a random date
Background
Individuals with narcolepsy or idiopathic hypersomnia present with a high comorbidity burden that may confer elevated risk for negative clinical outcomes associated with excess sodium intake.
The framing of sodium relevance suggests the study was motivated by treatments for these conditions that contain sodium (such as sodium oxybate)
The study concluded that careful management including limiting sodium exposure may mitigate the clinical burden in these populations
Both cohorts (narcolepsy and IH) showed substantially higher rates of all sodium-relevant risk factor categories compared to matched comparators
What This Means
This research suggests that people diagnosed with narcolepsy or idiopathic hypersomnia (IH) — sleep disorders characterized by excessive daytime sleepiness — are far more likely to have health conditions that make high sodium intake particularly risky. Using a large U.S. insurance claims database of over 40,000 patients with these sleep disorders and more than 200,000 comparison individuals without them, the researchers found that roughly 69% of people with narcolepsy and 74% of people with IH had at least one sodium-sensitive health condition such as heart disease, metabolic disorders, or kidney problems, compared to only about 43% of people without these sleep disorders.
The specific conditions found to be more common in narcolepsy and IH patients included cardiovascular problems (around 40% vs. 27% in comparators), cardiometabolic conditions like diabetes or obesity (around 50-52% vs. 35%), and kidney conditions (4-5% vs. 2-3%). These conditions are clinically important because excess sodium in the diet or in medications can worsen outcomes for people with heart, metabolic, and kidney diseases.
This research suggests that the already high health burden faced by people with narcolepsy or IH may be compounded if their sodium intake — including from medications used to treat their sleep disorders — is not carefully managed. The findings highlight the importance of monitoring and potentially limiting sodium exposure in people with these sleep conditions, particularly those who already have cardiovascular, cardiometabolic, or renal comorbidities.